Recent advances in understanding and managing psoriatic arthritis [version 1; referees: 2 approved]

by Dafna D. Gladman
Published 2016-11-01

Gradual Glucocorticosteroid Withdrawal Is Safe in Clinically Quiescent Systemic Lupus Erythematosus

by Konstantinos Tselios, Dafna D. Gladman, Jiandong Su, Murray B. Urowitz
Published 2021-08-01

Epigenome-wide analysis of sperm cells identifies IL22 as a possible germ line risk locus for psoriatic arthritis.

by Remy A Pollock, Laila Zaman, Vinod Chandran, Dafna D Gladman
Published 2019-01-01

The association between sonographic enthesitis and radiographic damage in psoriatic arthritis

by Ari Polachek, Richard Cook, Vinod Chandran, Dafna D. Gladman, Lihi Eder
Published 2017-08-01

Correction to: The association between sonographic enthesitis and radiographic damage in psoriatic arthritis

by Ari Polachek, Richard Cook, Vinod Chandran, Dafna D. Gladman, Lihi Eder
Published 2019-01-01

Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research

by Désirée van der Heijde, Dafna D. Gladman, Arthur Kavanaugh, Philip J. Mease
Published 2020-02-01

Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-...

by Philip J Mease, Dafna D Gladman, Laura C Coates, Sandra Navarra, Corine Gaillez, Weibin Bao
Published 2023-04-01

Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis

by Alexis Ogdie, Dafna D. Gladman, Laura C. Coates, Effie Pournara, Bhumik Parikh, Philip J. Mease
Published 2023-05-01

1303 The new EULAR/ACR 2019 SLE classification criteria: a predictor of long-term outcomes

by Murray B Urowitz, Dafna D Gladman, Sindhu R Johnson, Jiandong Su, Zahi Touma, Laura Whittall-Garcia
Published 2021-11-01

Methods for analyzing observational longitudinal prognosis studies for rheumatic diseases: a review & worked example using a clinic-based cohort of juvenile dermatomyositis patient...

by Lily Siok Hoon Lim, Eleanor Pullenayegum, Rahim Moineddin, Dafna D Gladman, Earl D Silverman, Brian M Feldman
Published 2017-03-01

1117 Neutrophil extracellular traps as a biomarker to predict outcomes in lupus nephritis

by Murray B Urowitz, Dafna D Gladman, Zahi Touma, Joan Wither, Laura Whittall-Garcia, Farnoosh Naderinavi, Anna Konvalinka
Published 2022-12-01

Circulating neutrophil extracellular trap remnants as a biomarker to predict outcomes in lupus nephritis

by Dafna D Gladman, Murray Urowitz, Zahi Touma, Joan Wither, Laura Patricia Whittall-Garcia, Farnoosh Naderinabi, Ana Konvalinka
Published 2024-05-01

Integrative Approach to Reveal Cell Type Specificity and Gene Candidates for Psoriatic Arthritis Outside the MHC

by Matthew T. Patrick, Philip E. Stuart, Kalpana Raja, Kalpana Raja, Sunyi Chi, Sunyi Chi, Zhi He, John J. Voorhees, Trilokraj Tejasvi, Trilokraj Tejasvi, Johann E. Gudjonsson, J. Michelle Kahlenberg, Vinod Chandran, Vinod Chandran, Vinod Chandran, Vinod Chandran, Vinod Chandran, Proton Rahman, Dafna D. Gladman, Dafna D. Gladman, Dafna D. Gladman, Rajan P. Nair, James T. Elder, James T. Elder, Lam C. Tsoi, Lam C. Tsoi, Lam C. Tsoi
Published 2019-04-01

The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus

by Lloyd Mai, Arundip Asaduzzaman, Babak Noamani, Paul R. Fortin, Dafna D. Gladman, Zahi Touma, Murray B. Urowitz, Joan Wither
Published 2021-01-01

Classification and Outcome Measures for Psoriatic Arthritis

by Ying Ying Leung, Alexis Ogdie, Ana-Maria Orbai, William Tillett, Laura C. Coates, Vibeke Strand, Philip Mease, Dafna D. Gladman
Published 2018-09-01

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo

by Dafna D. Gladman, Laura C. Coates, Joseph Wu, Lara Fallon, Elizabeth D. Bacci, Joseph C. Cappelleri, Andrew G. Bushmakin, Philip S. Helliwell
Published 2022-02-01

Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1–3 pooled analysis

by Arthur Kavanaugh, Dafna D. Gladman, Christopher J. Edwards, Georg Schett, Benoit Guerette, Nikolay Delev, Lichen Teng, Maria Paris, Philip J. Mease
Published 2019-05-01

Risk Stratification of Patients with Psoriatic Arthritis and Ankylosing Spondylitis for Treatment with Tofacitinib: A Review of Current Clinical Data

by Lars Erik Kristensen, Atul Deodhar, Ying-Ying Leung, Ivana Vranic, Mahta Mortezavi, Lara Fallon, Arne Yndestad, Cassandra D. Kinch, Dafna D. Gladman
Published 2024-05-01

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib

by Laura C. Coates, Andrew G. Bushmakin, Oliver FitzGerald, Dafna D. Gladman, Lara Fallon, Joseph C. Cappelleri, Ming-Ann Hsu, Philip S. Helliwell
Published 2021-03-01

Rho-GTPase pathways may differentiate treatment response to TNF-alpha and IL-17A inhibitors in psoriatic arthritis

by Sara Rahmati, Darren D. O’Rielly, Quan Li, Dianne Codner, Amanda Dohey, Kari Jenkins, Igor Jurisica, Dafna D. Gladman, Vinod Chandran, Proton Rahman
Published 2020-12-01